Interleukin‐21 Receptor Blockade Inhibits Secondary Humoral Responses and Halts the Progression of Preestablished Disease in the (NZB × NZW)F1 Systemic Lupus Erythematosus Model
Authors:
Open Access
- 19 June 2015
- journal article
- systemic lupus-erythematosus
- Published by Wiley in Arthritis & Rheumatology
- Vol. 67 (10) , 2723-2731
Abstract
Objective: Systemic lupus erythematosus (SLE) is a complex autoimmune disease that is driven in part by chronic B and T lymphocyte hyperresponsiveness to self antigens. A deficiency of interleukin‐21 (IL‐21) or IL‐21 receptor (IL‐21R) in mice dramatically reduces inflammation and B and T cell activation in models of autoimmunity, including SLE. However, whether IL‐21 is essential for the maintenance and amplification of preestablished inflammation has not been widely examined in various animal models. The purpose of this study was to examine the impact of novel mouse IL‐21R neutralizing antibodies on recall responses to antigen challenge and on disease progression in the (NZB × NZW)F1 (NZB/NZW) mouse model of SLE.Methods: Humoral and cellular immune responses to immunization with sheep red blood cells (SRBCs) were measured in mice dosed with IL‐21R blocking antibodies. Progression of nephritis and markers of immune activation was monitored in NZB/NZW mice following different anti–IL‐21R treatment regimens.Results: IL‐21R blockade specifically inhibited secondary IgG responses to SRBC immunization. In NZB/NZW mice, IL‐21R blockade completely inhibited the onset of nephritis, which was associated with dramatic reductions in splenomegaly and in B cell and T cell activation. When administered to mice with preexisting disease, anti–IL‐21R antibody halted the disease progression and mortality and reversed the nephritis in a subset of mice. Furthermore, treatment cessation was not followed by rapid reemergence of disease.Conclusion: Our results highlight the importance of IL‐21 in promoting humoral recall responses and in sustaining autoimmune inflammation.Keywords
Funding Information
- Amgen, Inc.
This publication has 46 references indexed in Scilit:
- Genetic Variation at a Yin-Yang 1 Response Site Regulates the Transcription of Cyclin-Dependent Kinase Inhibitor p18INK4C Transcript in Lupus-Prone MiceThe Journal of Immunology, 2012
- IL-21 Receptor Is Required for the Systemic Accumulation of Activated B and T Lymphocytes in MRL/MpJ-Faslpr/lpr/J MiceThe Journal of Immunology, 2012
- IL-21 Promotes Skin Recruitment of CD4+ Cells and Drives IFN-γ–Dependent Epidermal HyperplasiaThe Journal of Immunology, 2011
- Murine lupus susceptibility locus Sle2 activates DNA-reactive B cells through two sub-loci with distinct phenotypesGenes & Immunity, 2011
- Murine lupus susceptibility locus Sle1a requires the expression of two sub-loci to induce inflammatory T cellsGenes & Immunity, 2010
- IL-21 Is Required to Control Chronic Viral InfectionScience, 2009
- A Positive Feedback Loop of IL-21 Signaling Provoked by Homeostatic CD4+CD25− T Cell Expansion Is Essential for the Development of Arthritis in Autoimmune K/BxN MiceThe Journal of Immunology, 2009
- ICOS Controls Effector Function but Not Trafficking Receptor Expression of Kidney-Infiltrating Effector T Cells in Murine LupusThe Journal of Immunology, 2009
- A critical role for IL-21 receptor signaling in the pathogenesis of systemic lupus erythematosus in BXSB-YaamiceProceedings of the National Academy of Sciences, 2009
- Increased Foxp3+ CD4+ Regulatory T Cells with Intact Suppressive Activity but Altered Cellular Localization in Murine LupusThe American Journal of Pathology, 2008